-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

Benzinga·07/13/2026 10:50:58
語音播報
Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $84 to $120.